Athenaeum Fund is supported by several individual and corporate investors from across the
United States. The Athenaeum Fund IV's management comprises three managing members and an advisory board. The managing
members have over 50 years of experience of profitable investing, starting successful companies and
The Athenaeum Fund was originally founded in 1999 by Dr. John Baldeschwieler, Malcolm Cloyd and John Glanville.
|| Dr. Philippe H. Adam
is a Founder and General Partner of The Athenaeum Fund IV as well as a Special Limited Partner in the Athenaeum Fund III.
Dr. Adam is an all-around senior strategy, business development and investment professional with 20+ years of global
experience in technology and business, and with a track record of sourcing new investment opportunities, launching new business
and helping companies grow. He has worked and consulted for a number of research labs, companies and firms including Caltech/NASA's
Jet Propulsion Lab, AlliedSignal/Honeywell, Houlihan Lokey, Avery Dennison, and Beckman Coulter. His experience also spans a
variety of industries ranging from Aerospace & Defense, Automotive, Cleantech and Healthcare/Medical Devices
to Software, Wireless/RFID, Consumer Products/Electronics and Retail.
Currently, Dr. Adam also serves as an advisor to Maximillian Gallery, a start-up exploring new business models to monetize
emerging art IP, and to Advanced TeleSensors, a start-up from Caltech/JPL commercializing a contactless vitals monitoring
technology for consumer and health/medical applications.
Dr. Adam holds undegraduate degrees in Aerospace Engineering and Applied Mathematics from Polytechnic University in Brooklyn, NY
and he received his M.S. and Ph.D. in Aeronautics from the California Institute of Technology in Pasadena, CA. He also holds an MBA
from the Wharton School of the University of Pennsylvania.
|| Dr. John D. Baldeschwieler
is one of the original Founders and General Partners of The Athenaeum Fund.
He received a degree in Chemical Engineering from Cornell University
in 1956 and in 1959 a Ph.D. in Physical Chemistry from the University
of California, Berkeley. His military service in the U.S. Army was
followed by five years of teaching and research as a member of the
faculty at Harvard University. In 1965, he moved to Stanford as Professor
of Chemistry. During his last two years at Stanford, he was on leave
of absence as Deputy Director of the Office of Science and Technology
in the White House. From 1973 until the present, Professor Baldeschwieler
has been at the California Institute of Technology as Professor of
Chemistry, and for five years also as Chairman of the Division of
Chemistry and Chemical Engineering.
A Fellow of the National Academy of Sciences, American Academy
of Arts and Sciences and the American Philosophical Society, Dr.
Baldeschwieler also served on a large number of national, scientific
and advisory committees, as well as on the editorial boards of several
journals. He has most recently served as Chairman of the Academy
Committee on Commercial Aviation Security, as an advisor to the
FAA, as a member of the Presidential Commission on Gulf War Veterans
Illnesses, and the National Academy of Sciences Committee on Science
and Technology for Countering Terrorism, and as Co-Chairman of the
National Science Foundation-US Intelligence Community Workshop On
Approaches to Combating Terrorism. He was a founder of Vestar Inc.
and served as Chairman of its Board of Directors until it was merged
with NeXagen Inc. to form NeXstar Pharmaceuticals. He served as
a Director of NeXstar until it was acquired by Gilead Pharmaceuticals
Inc. He was also a founder and Director of Combion Inc. until it
was acquired by Incyte Geonomics, Inc.
Dr. Baldeschwieler pioneered the utilization of nuclear magnetic
resonance and double resonance spectroscopy, nuclear Overhauser
effects, ion cyclotron resonance and perturbed angular correlation
spectroscopy in chemical problems. His latest contributions concentrate
on the use of phospholipid vesicles in cancer diagnosis and therapy,
on the development of scanning tunneling and atomic force microscopy
for the study of molecules on surfaces, and on novel techniques
for producing combinatorial arrays of oligonucleotides. He received
the 2000 National Medal of Science for his contributions to science
and public service, the American Chemical Society 2001 Award for
Creative Invention and the 2003 Othmer Gold Medal of the Chemical
Currently, Dr. Baldeschwieler serves on the Boards of the Huntington
Medical Research Institutes (Pasadena, CA) and the Keck Graduate Institute
(Claremont, CA), as well as several privately held companies.
|| Malcolm Cloyd is
one of the original Founders and General Partners of The Athenaeum Fund.
He has served as President, Vice President and General Manager of manufacturing
and service businesses with domestic and international markets for
over 27 years. He has directed business units that were the largest
cash contributors for two major corporations and has conducted turnarounds
of under-performing businesses for both large corporations and privately
Mr. Cloyd has been heavily involved with marketing and has directed
the development and commercialization of new products and services.
He assisted with the development of an information service that
was used in the oil and gas industry, which utilized the combined
technology of geophysical and electronic well logging. He also helped
to develop the first use of solid state electronic controllers with
large electric motors and other equipment to improve the operating
efficiency of large-scale applications.
Mr. Cloyd has served on the Board of portfolio companies Language Weaver
and Syagen and continues to serve on the Board of Eidogen-Sertanty, a
bioinformatics portfolio company with offices in Oceanside, CA. Currently,
he also serves on the Boards of InterMarine Inc. (Houston, TX) and Advanced
TeleSensors (Pasadena, CA).
Mr. Cloyd has degrees in management, science and literature.